Analysis of blood plasma could help identify diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis, according to new research.
The work sheds further light on a pathway involved in disease progression and appears to rule out an environmental neurotoxin as playing a role in ALS.
ALS is a progressive neurodegenerative disease that causes deterioration of nerve cells in the brain and spinal cord. Currently, a lack of definitive targets, a diagnostic process that often takes over a year to complete, and insufficient and subjective methods for monitoring progression hamper treatments.
“…a panel of plasma metabolites could be used both for diagnosis and as a way to monitor disease progression.”
“Early diagnosis is important, but we are in dire need of quantitative markers for monitoring progression and the efficacy of therapeutic intervention,” says Michael Bereman, associate professor of biological sciences at North Carolina State University and corresponding author of the paper on the work in the Journal of Proteome Research.
“Since disruptions in metabolism are hallmark features of ALS, we wanted to investigate metabolite markers as an avenue for biomarker discovery.”
The researchers took blood plasma samples for 134 ALS patients and 118 healthy individuals from the Macquarie University MND Biobank. They used chip-based capillary zone electrophoresis coupled to high resolution mass spectrometry to identify and analyze blood plasma metabolites in the samples.
This method quickly breaks the plasma down into its molecular components, which are then identified by their mass. The researchers developed two computer algorithms: one to separate healthy and ALS samples and the other to predict disease progression.
The researchers found the most significant metabolism markers were associated with muscle activity: elevated levels of creatine, which aids muscle movement, and decreased levels of creatinine and methylhistidine, which are byproducts of muscle activity and breakdown. Creatine was 49% elevated in ALS patients, while creatinine and methylhistindine decreased by 20% and 24%, respectively. Additionally, the ratio of creatine versus creatinine increased 370% in male, and 200% in female, ALS patients.
Through machine learning, the algorithms that the researchers created were then able to both separate healthy participants from ALS patients and predict the progression of the disease. The models produced results for both sensitivity (ability to detect disease), and specificity (ability to detect individuals without disease). The disease detection model performed at 80% sensitivity and 78% specificity, and the progression model performed at 74% sensitivity and 87% specificity.
“Creatine deficiency alone does not seem to be a problem—our results confirm that the creatine kinase pathway of cellular energy production, known to be altered in ALS, is not working as well as it should,” Bereman says.
“These results are strong evidence that a panel of plasma metabolites could be used both for diagnosis and as a way to monitor disease progression,” says coauthor Gilles Guillemin, professor of neurosciences at Macquarie University. “Our next steps will be to examine these markers over time within the same patient.”
Another goal of the work was to look for evidence of exposure to an environmental neurotoxin, Beta Methylamino-L-Alanine (BMAA), which is in green and blue algae blooms. BMAA has been associated with ALS since the 1950s, but few studies have attempted to detect it in human ALS patients. The researchers did not detect BMAA in the blood of either healthy or ALS patients.
Additional researchers from NC State and Australia’s Macquarie University contributed to the work.
Support for the research came, in part, from the ALS Biomarker Consortium, ALS Association, ALS Finding a Cure, the Packard Association for ALS, and the Chancellor’s Innovation Fund at NC State University.
Source: NC State